Skip to main content
. 2023 Feb 28;14:1134371. doi: 10.3389/fimmu.2023.1134371

Figure 4.

Figure 4

Immune serum from LGTV infected mice protects mice against subsequent TBEV challenge infection. Serum pooled from the respective group was i.p. injected into recipient mice (n=5). Following TBEV challenge infection, body weight of mice that received (A) control serum or (B) LGTV immune serum was monitored over a period of 16 dpi. Mice were taken out of experiment when the HEP was reached. (C) Survival curve plotted for the recipient mice that received control serum (dotted line) or serum from LGTV infected mice (solid line). Significant difference was analyzed by log rank test (p = 0.033). (D) TCID50 was performed on serum and tissue homogenates to determine the viral load in serum, spleen, brain and spinal cord of control (•) or LGTV (Δ) serum recipients collected at the day of sacrifice. Median values are shown. Mice that differed in their clinical state from other mice in the control and LGTV serum recipient group are highlighted as rhombus shaped symbols. *p<0.05.